Skip to main content
Fig. 1 | Radiation Oncology

Fig. 1

From: Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer

Fig. 1

Axial (upper) and coronal (lower) computed tomography (CT) images of a representative patient

Interstitial lung disease/radiation pneumonitis (ILD/RP) arising from the low-dose irradiated area after chemoradiotherapy (CRT) in patient #10 in Table 3. (a): On the 37th day after the completion of CRT, the patient had received 3 cycles of durvalumab before discontinuing due to diagnosis of Grade 2 ILD/RP. The shadow disappeared soon after initiation of prednisone (PSL, 80 mg/day = 1 mg/kg/day). (b): On the 89th day, when PSL was being tapered to 20 mg/day, infiltrative shadows and ground-glass opacities reappeared and spread over the irradiated area with worsened dyspnea, leading to diagnosis of Grade 3 ILD. (c): On the 173rd day, the infiltrative shadow and ground-glass opacities disappeared after increasing the dose of PSL, but fibrosis appeared limited to the high-dose irradiated areas. (d): axial and (e): coronal CT images show the radiotherapy dose distribution in this patient

Back to article page